Company Overview
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. Acasti may need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre’s indications to this segment. Acasti’s strategy is to commercialize CaPre in the U.S. and the company is pursuing development and distribution partnerships to market CaPre in major countries around the world.

Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
Mar 11 2020, 12:00 AM EDT

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
Feb 28 2020, 12:00 AM EST

Stock Overview
<table>
<thead>
<tr>
<th>Symbol</th>
<th>ACST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>32.55m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$0.36</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$0.25 - $3.08</td>
</tr>
</tbody>
</table>

Investor Relations
Crescendo Communications, LLC
626 RXR Plaza
Uniondale, NY 11566
T: 212-671-1020
ACST@crescendo-ir.com

Management Team
Jan D’Alvise
President and CEO

Pierre Lemieux, Ph.D.
Chief Operating and Scientific Officer, Co-Founder

Brian Groch
Chief Commercial Officer

Jean-François Boily, CPA, CA
Vice-President, Finance

Acasti Pharma Inc.
545 Promenade du Centropolis
Suite 100, Laval
Québec H7T 0A3
Canada

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.